Has Waasil Kareem, MD received payments from drug or device companies?

Yes. Drug and device makers reported $154,033 in general payments to Waasil Kareem, MD across 194 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Waasil Kareem, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Waasil Kareem, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Waasil Kareem, MD

Pulmonary Disease · Duarte, CANPI 1588003602

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (49.5%), speaking fees and grants — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 79.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $50,000 and has fallen 57.8% since, to $21,112 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$154,033in general payments, 2019–2025

Across 194 payments — averaging $793.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$122K
Boston Scientific$30K
Johnson & Johnson$679
Galvanize Therapeutics, Inc$372
Olympus America Inc.$283
Pulmonx Corporation$138
plus $523 from 9 others

What the payments were for

Speaking & faculty fees$38,00025%
Grants$30,00019%
Travel & lodging$2,2031%
Food & beverage$7,6305%
Education$76,20049%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	166	$122,016
Boston Scientific	4	$30,022
Johnson & Johnson	7	$679
Galvanize Therapeutics, Inc	2	$372
Olympus America Inc.	2	$283
Pulmonx Corporation	1	$138
Siemens Medical Solutions USA, Inc.	1	$129
Eisai Inc.	1	$122
Pinnacle Biologics, Inc	1	$59
Fujifilm Healthcare Americas Corporation	2	$48
AstraZeneca	2	$43
ERBE USA Inc	2	$40
Takeda Pharmaceuticals U.S.A., Inc.	1	$30
Philips North America LLC	1	$26
Bayer	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,033 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Medicare billing

Part B allowed, 2024

$187,146

Medicare patients

431

Services billed

1,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	75	$49,327
Incruse ElliptaUmeclidinium Bromide	12	$4,138
Albuterol Sulfate HfaAlbuterol Sulfate	61	$1,969
Ventolin HfaAlbuterol Sulfate	14	$767
Azithromycin	30	$125
Montelukast Sodium	17	$108
Prednisone	19	$57

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Duarte

Samuel LouieSacramento$2.8M
Shyamsunder SubramanianTracy$1.5M
Toby MaherLos Angeles$1.3M
Rajkumar DasguptaPasadena$930K
Hoang leFountain Valley$814K
Kevin FussellEncinitas$788K
Revati ShreeniwasStanford$726K
David PhamWestminster$571K
Vijay BalasubramanianFresno$529K
Victor TapsonLos Angeles$514K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →